Bacteria learned to tolerate one drug, and one drug alone.
In the long struggle between medicine and microbial adaptation, a laboratory in Tübingen has observed something quietly remarkable: when pushed to the edge of survival by colistin — humanity's antibiotic of last resort — E. coli learned to endure that single pressure without broadening its defenses against anything else. The finding challenges the familiar fear that resistance begets more resistance, suggesting that under certain conditions, bacterial adaptation can be narrow, specific, and perhaps more containable than we have assumed. The full meaning of this discovery, however, awaits the messier tests of clinical reality.
- Colistin is the antibiotic clinicians reach for when all others have failed, making any sign of bacterial resistance to it a matter of serious concern.
- Under escalating colistin pressure in a controlled spatial evolution experiment, E. coli achieved a 128-fold increase in tolerance — a dramatic leap that could signal the closing of medicine's last door.
- Yet when tested against a panel of other antibiotics, the resistant bacteria showed no new defenses — a surprising absence of the collateral resistance that typically shadows such adaptations.
- Genomic sequencing revealed only sparse, subtle changes in envelope-related genes, leaving the true molecular mechanism of resistance frustratingly unclear and possibly hidden in gene expression or efflux activity.
- The study's single-strain, single-laboratory design means its reassuring conclusion — that resistance here was compound-specific — cannot yet be carried into hospitals, farms, or the complex ecosystems where colistin resistance truly matters.
Colistin is medicine's antibiotic of last resort, deployed only when nearly everything else has failed. Yet what happens inside a bacterium as it begins to adapt to colistin has remained poorly understood. A new study from the University of Tübingen offers a surprising answer.
Researchers placed E. coli on a MEGA-plate — a spatial evolution arena that exposes migrating bacteria to stepwise increases in antibiotic concentration. Across three independent experiments, bacteria navigated zones ranging from no colistin to one thousand times the standard dose. Those that survived the highest concentrations had transformed their tolerance dramatically: resistance jumped 128-fold, from 0.5 to 64 micrograms per milliliter.
The unexpected finding came next. When these resistant isolates were tested against other antibiotics, nothing had changed — they remained just as vulnerable as before. Conventional wisdom predicts that resistance to one drug often brings collateral resistance to others, sometimes through shared genetic machinery. That did not happen here.
Genome sequencing offered only partial explanation. No plasmids or mobile resistance genes were found. The only detected variants were sparse mutations in envelope-associated genes — a missense change in ftsI at high exposure, a synonymous change in ompC at low exposure — subtle alterations that seem insufficient to account for such a large shift in tolerance. Efflux pumps or regulatory changes may be responsible, but without transcriptomic data, that remains speculation.
The study's limits are real: one bacterial strain, one laboratory setting, no functional assays, and only single isolates sequenced per zone. Whether this compound-specific adaptation pattern holds in clinical infections, mixed microbial communities, or under different selection pressures is entirely unknown. What the researchers have produced is a narrow but meaningful observation — that under these conditions, E. coli adapted to colistin alone, without becoming something more dangerous. One corner of the resistance landscape has been mapped; the rest remains in shadow.
Colistin occupies a peculiar place in medicine—it is the drug we reach for when everything else has failed, a last resort for infections caused by bacteria resistant to nearly all other antibiotics. Yet little has been known about what happens inside a bacterium when it begins to adapt to colistin itself. A new laboratory study offers an unexpected answer: the bacteria evolved resistance to colistin alone, without picking up the ability to resist other drugs.
Researchers at the University of Tübingen grew Escherichia coli in a specialized petri dish called a MEGA-plate—a spatial evolution arena that allows bacteria to migrate across zones of increasing antibiotic concentration. They ran three independent experiments, exposing the same strain of E. coli to stepwise increases in colistin pressure. As the bacteria spread across the gradient, they encountered five different colistin concentrations: none, one times the standard dose, ten times, one hundred times, and one thousand times. The bacteria that survived at the highest concentrations had undergone a dramatic shift in their tolerance. Their resistance to colistin jumped from 0.5 micrograms per milliliter to 64—a 128-fold increase.
But here is where the story becomes surprising. When the researchers tested these same resistant isolates against other antibiotics, nothing had changed. The bacteria remained just as vulnerable to every other drug they tested. This is not what conventional wisdom would predict. Typically, when bacteria evolve resistance to one antibiotic, they often develop collateral resistance—the ability to shrug off multiple drugs at once, sometimes through the same genetic mechanism. That did not happen here.
To understand why, the team sequenced the genomes of representative isolates from each exposure zone. They found no evidence of plasmid-mediated resistance—no mobile genetic elements carrying resistance genes that could be shared with other bacteria. The standard database of known resistance genes showed no new additions. Instead, the genetic changes were sparse and subtle. A few variants appeared in genes related to the bacterial cell envelope: a missense mutation in ftsI showed up in the highest-exposure isolates, and a synonymous change in ompC appeared in the lowest-exposure group. These are not the kinds of dramatic rewrites you might expect to underpin a 128-fold shift in resistance.
The researchers acknowledge the limits of what they can conclude. They sequenced only one representative isolate from each exposure zone, not all nine endpoint isolates they collected. They did not measure gene expression or run functional assays to see whether the bacteria were ramping up efflux pumps or other regulatory systems that might explain the resistance without leaving obvious genetic fingerprints. The study was also confined to a single bacterial strain under controlled laboratory conditions—a far cry from the messy reality of infections in human bodies or the complex microbial communities in hospitals and farms.
What emerges from this work is a narrow but important finding: under these specific experimental conditions, E. coli adapted to colistin through a compound-restricted mechanism. The bacteria did not become a multi-drug-resistant superorganism. They simply learned to tolerate one drug, and one drug alone. Whether this pattern holds in clinical settings, in mixed bacterial populations, or under different selection pressures remains an open question. The researchers have mapped one corner of the resistance landscape, but the full terrain is still largely unmapped.
Citações Notáveis
These data support a compound-restricted phenotypic response in this single-strain model under the conditions tested.— Study authors
Broader regulatory adaptation or efflux-related responses cannot be excluded.— Study authors
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that colistin resistance didn't trigger cross-resistance? Isn't that good news?
It's more complicated than that. Colistin is the drug we use when we've already lost everything else. If bacteria could evolve resistance to it without also gaining resistance to other drugs, that's actually a narrow window—it means the resistance mechanism is specific, not a general unlock. But it also means we need to understand what that mechanism is, because it might be exploitable.
So the bacteria didn't pick up any new resistance genes at all?
Not that they could find. No plasmids, no new entries in the standard resistance database. Just a handful of small mutations in genes related to the cell envelope. It's like the bacteria solved the colistin problem through fine-tuning rather than wholesale rewiring.
But they only sequenced one isolate per exposure level. Doesn't that seem like a gap?
A significant one, yes. They collected nine isolates total but only read the genome of three. They're being honest about it—they note that transcriptomic work and functional assays could reveal mechanisms that DNA sequencing alone can't see. Efflux pumps, for instance, could be doing heavy lifting without leaving obvious genetic traces.
What would change if they'd done those experiments?
We might discover that the bacteria are actually deploying more complex regulatory systems than the mutations suggest. Or we might find that the resistance is even more fragile than it appears. Right now, we're looking at the skeleton of the story, not the full body.
Does this tell us anything about what happens in real infections?
Not directly. This is a single strain in a petri dish under very controlled conditions. Real infections involve mixed bacterial populations, immune systems, and the chaos of a living body. The findings are a proof of concept—resistance to colistin can evolve narrowly—but the clinical relevance is still an open question.